Nova Leah, a Dundalk headquartered medical device security company has secured a deal with Fresenius Medical Care, a major supplier of dialysis products.
Fresenius will implement Nova Leah’s cybersecurity risk management tool SelectEvidence, which is designed for connected medical devices.
The tool is intended to guide medical device manufacturers implementing cybersecurity requirements and best practices over the lifetime of devices in compliance with US FDA recommendations during premarket and post market activities.
Nova Leah, which has opened an office in Boston, is initially targeting customers in the imaging and electro medical device sectors in the US, a market that is estimated to be worth $155 billion, of which connected devices account for approximately $51 billion.
